NEWS
Our Latest News
ARCHIMED acquires SeqCenter, a fast-growing player in cutting-edge DNA and RNA gene sequencing
SeqCenter is a category leader in Next-Generation Sequencing, which can sequence hundreds of thousands of genes in record-time and at low cost.
Global private equity healthcare specialist ARCHIMED announces the acquisition of Pittsburgh, Pennsylvania-based genetic sequencing provider SeqCenter. SeqCenter’s founding scientists initially worked at the University of Pittsburgh. Frustrated with the pace, cost and difficulty of obtaining sequencing data from existing vendors and academic core laboratories, they developed their own approach to gene sequencing, ultimately leaving academia and founding SeqCenter in 2019.
ARCHIMED buys Cube, an innovative provider of membrane protein services for the biopharma research market
November
3,
2021
ARCHIMED refinances Ad-Tech less than a year after purchase, returning more than a third of investment to shareholders
October
20,
2021
ARCHIMED’s NAMSA returns more than a third of investment
October
7,
2021
368